Clinical risk predictors for differentiated thyroid cancer management: what is new?
- PMID: 30864624
- PMCID: PMC10118835
- DOI: 10.20945/2359-3997000000110
Clinical risk predictors for differentiated thyroid cancer management: what is new?
Conflict of interest statement
Disclosure: no potential conflict of interest relevant to this article was reported.
Comment on
-
Impact of the updated TNM staging criteria on prediction of persistent disease in a differentiated thyroid carcinoma cohort.Arch Endocrinol Metab. 2019 Feb;63(1):5-11. doi: 10.20945/2359-3997000000097. Arch Endocrinol Metab. 2019. PMID: 30864625 Free PMC article.
-
Does the Bethesda category predict aggressive features in differentiated thyroid cancer?Arch Endocrinol Metab. 2019 Feb;63(1):12-15. doi: 10.20945/2359-3997000000098. Arch Endocrinol Metab. 2019. PMID: 30864626 Free PMC article.
References
-
- Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am. 2014;43(2):401-21. - PubMed
-
- Haugen BR, Alexander EK, Bible KC, Mandel SJ, Nikiforov YE, Pacini F, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical